Outlook Therapeutics
Edit info- Founded: 2011
- Location: Iselin, NJ
- Employee range: 1-50
- Clinical stage: BLA
- Therapy area: Wet AMD
- Drug types: OPH, GER
- Lead product: ONS-5010
- Funding: 100-500M
outlooktherapeutics.com linkedin.com job board
Business:
Biosimilars
Drug notes:
Also Clin0 branch retinal vein occlusion, Clin0 DME
About:
Outlook Therapeutics is developing antibody-based therapeutics for ophthalmic disorders. Wet age-related macular degeneration (Wet AMD) is the leading cause of vision loss among people over age 50 and is triggered by abnormal blood vessel growth. Bevacizumab-vikg is a recombinant humanized monoclonal antibody that antagonizes the activity of the protein VEGF, a protein that regulates blood vessel formation. Outlook is developing the first ophthalmic formulation of bevacizumab that can be delivered to patients via intravitreal injection. Following injection and VEGF inhibition, vascular leakage can be reduced with the potential of deploying the therapy for patients with wet AMD.
Jobs:
News:
Outlook Therapeutics® Streamlines Operations | Outlook Therapeutics, Inc.
linkedin
Dec 20, 2024
Science/business updates
external-link
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
crunchbase
Dec 2, 2024
Funding-related
external-link
Preliminary option volume of 59.7M today
crunchbase
Dec 13, 2024
Science/business updates
external-link
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - Yahoo Finance
googlenews
Aug 14, 2024
Science/business updates
external-link
Outlook Therapeutics stock jumps as EU backs new wet AMD treatment (NASDAQ:OTLK)
crunchbase
Mar 24, 2024
Science/business updates
external-link
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private ...
crunchbase
Jun 23, 2024
Funding-related
external-link
At Outlook Therapeutics, we envision a future with better therapies for vision preservation. Learn about our mission: https://bit.ly/46Hmqx0
#OTLK #Ophthalmology #RetinaDisease #WetAMD
linkedin
Nov 27, 2024
Science/business updates
external-link
Outlook Therapeutics® Streamlines Operations - Yahoo Finance
googlenews
Dec 13, 2024
Science/business updates
external-link
Age-related Macular Degeneration Treatment Market 2034: FDA Approvals, Drugs, Medication, and Companies by DelveInsight
crunchbase
Dec 27, 2024
Science/business updates
external-link
Outlook Therapeutics announces NICE recommendation of LYTENAVA - TipRanks
googlenews
Dec 4, 2024
Science/business updates
external-link
Outlook Therapeutics® Announces Executive Leadership Transition - Yahoo Finance
googlenews
Dec 3, 2024
New hires
external-link
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial | Outlook Therapeutics, Inc.
linkedin
Nov 29, 2024
Science/business updates
external-link
Outlook Therapeutics files to sell 21.43M common shares for holders
crunchbase
Mar 25, 2024
Funding-related
external-link
Velan Capital Investment Management LP Increases Stake in Outloo - GuruFocus.com
googlenews
Nov 8, 2024
Funding-related
external-link
Outlook Therapeutics to reduce workforce by 23%, streamline operations - TipRanks
googlenews
Dec 13, 2024
New hires
external-link
Outlook Therapeutics completes NORSE EIGHT enrollment - Investing.com
googlenews
Sep 4, 2024
Science/business updates
external-link
Outlook Therapeutics: Speculative Buy With High Stakes In Anti-VEGF Market (NASDAQ:OTLK)
crunchbase
Jun 16, 2024
Science/business updates
external-link
Outlook Therapeutics Shares Rise Premarket on CHMP Backing of Wet AMD Drug
crunchbase
Apr 3, 2024
Science/business updates
external-link
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split - GlobeNewswire
googlenews
Mar 12, 2024
Funding-related
external-link
Outlook Therapeutics to reduce workforce by 23%, streamline operations
crunchbase
Dec 13, 2024
Science/business updates
external-link
Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial - Yahoo Finance
googlenews
Nov 27, 2024
Science/business updates
external-link
VIDEO: Outlook Therapeutics enrolling patients in trial of ONS-5010 - Healio
googlenews
Jun 27, 2024
Science/business updates
external-link
Cencora assumed with an Outperform at Mizuho
crunchbase
Dec 3, 2024
Science/business updates
external-link
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab ...
crunchbase
May 30, 2024
Science/business updates
external-link
Our commitment to advancing retinal therapies is fueled by our passionate team. Discover their stories: https://bit.ly/4ccRdTD
#OTLK #ophthalmology #retinadisease #wetAMD
linkedin
Nov 27, 2024
New hires
external-link
Outlook Therapeutics (OTLK) Reports Prelim Topline Results of NORSE EIGHT Trial
crunchbase
Nov 27, 2024
Science/business updates
external-link
Chardan Capital Downgrades Outlook Therapeuti...
crunchbase
Dec 2, 2024
Science/business updates
external-link
Outlook Therapeutics names interim CEO, plans product launch - Investing.com
googlenews
Dec 3, 2024
New hires
external-link
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD | Outlook Therapeutics, In...
linkedin
Dec 6, 2024
Science/business updates
external-link
BTIG lowers Outlook Therapeutics stock price target, but sees growth potential in Europe - Investing.com
googlenews
Nov 29, 2024
Science/business updates
external-link
Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Simply Wall St
googlenews
Nov 2, 2024
Science/business updates
external-link
Private equity firms are Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners and were rewarded after market cap rose by US$30m last week - Simply Wall St
googlenews
Sep 10, 2024
Funding-related
external-link
Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series - AccessWire
googlenews
Jun 12, 2024
Science/business updates
external-link
Outlook Therapeutics® Doses First Subject in NORSE EIGHT - GlobeNewswire
googlenews
Jan 31, 2024
Science/business updates
external-link
Outlook Therapeutics' LYTENAVA Secures Groundbreaking NICE Recommendation for Wet AMD Treatment - StockTitan
googlenews
Dec 4, 2024
Science/business updates
external-link
Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK), - Yahoo Finance
googlenews
Nov 26, 2024
Funding-related
external-link
Great Point Partners LLC Bolsters Position in Outlook Therapeuti - GuruFocus.com
googlenews
Nov 15, 2024
Funding-related
external-link
This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
crunchbase
Dec 2, 2024
Science/business updates
external-link
Pure Storage reports Q3 non-GAAP EPS 50c, consensus 42c
crunchbase
Dec 3, 2024
Science/business updates
external-link
Outlook Therapeutics Trial of Eye Disease Treatment Misses Key Endpoint - MarketWatch
googlenews
Nov 27, 2024
Science/business updates
external-link
Outlook's shares crash as wet AMD drug flunks Phase 3 test
crunchbase
Nov 27, 2024
Science/business updates
external-link
Outlook Therapeutics® Announces Executive Leadership Transition | Outlook Therapeutics, Inc.
linkedin
Dec 6, 2024
New hires
external-link
Outlook Therapeutics® Announces NICE Recommendation of - GlobeNewswire
googlenews
Dec 4, 2024
Science/business updates
external-link
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outlook Therapeutics, Inc. - OTLK - PR Newswire
googlenews
Dec 2, 2024
Funding-related
external-link
Chardan cuts Outlook Therapeutics to neutral on study data - Investing.com
googlenews
Dec 2, 2024
Science/business updates
external-link
Outlook Therapeutics CEO Steps Down Amid Key Drug Launch; Names Interim Leader - StockTitan
googlenews
Dec 3, 2024
New hires
external-link
Outlook Therapeutics' Eye Drug Falls Short in Phase 3 Trial, Misses Key Endpoint - StockTitan
googlenews
Nov 27, 2024
Science/business updates
external-link
Outlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial Launch - MarketWatch
googlenews
Dec 13, 2024
Science/business updates
external-link
Outlook Therapeutics Cuts 23% of Workforce Following EU Approval of Key Eye Treatment LYTENAVA - StockTitan
googlenews
Dec 13, 2024
New hires
external-link
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
crunchbase
Nov 27, 2024
Science/business updates
external-link
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
googlenews
Oct 11, 2024
Funding-related
external-link
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private equity firms own 31% - Yahoo Finance
googlenews
Jun 19, 2024
Funding-related
external-link
Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside - MarketBeat
googlenews
Jun 19, 2024
Science/business updates
external-link
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
crunchbase
May 28, 2024
Science/business updates
external-link
Outlook Therapeutics reports Q2 EPS ($8.01) vs. (52c) last year
crunchbase
May 15, 2024
Science/business updates
external-link
Outlook Therapeutics® Streamlines Operations - The Manila Times
googlenews
Dec 14, 2024
Science/business updates
external-link
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
crunchbase
Apr 15, 2024
Funding-related
external-link
Outlook Therapeutics files $300M mixed securities shelf
crunchbase
Mar 28, 2024
Funding-related
external-link
Outlook Therapeutics stock still a Buy rating despite trial miss - Investing.com
googlenews
Nov 29, 2024
Science/business updates
external-link
Outlook's stock plummets after eye drug fails to match Lucentis, but biotech still plans FDA filing - Fierce Biotech
googlenews
Nov 27, 2024
Science/business updates
external-link
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
crunchbase
Jun 11, 2024
Funding-related
external-link
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - Yahoo Finance
googlenews
Jul 8, 2024
Science/business updates
external-link
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
crunchbase
May 30, 2024
Science/business updates
external-link
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a ...
crunchbase
May 30, 2024
Science/business updates
external-link
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase - GlobeNewswire
googlenews
Apr 29, 2024
Science/business updates
external-link
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
web
Jan 2, 2025
Science/business updates
external-link
Outlook culls 23% of staff as it eyes FDA resubmission, EU debut - Fierce Biotech
googlenews
Dec 16, 2024
New hires
external-link
Outlook Therapeutics CEO to Present at Guggenheim Healthcare Conference After EU Win - StockTitan
googlenews
Nov 6, 2024
Science/business updates
external-link
Outlook Therapeutics price target lowered to $9 from $50 at BTIG - Yahoo Finance
googlenews
Nov 30, 2024
Science/business updates
external-link
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial - Yahoo Finance
googlenews
Sep 4, 2024
Science/business updates
external-link
Outlook stock plunges after study setback (OTLK:NASDAQ) - Seeking Alpha
googlenews
Nov 27, 2024
Science/business updates
external-link
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment - StockTitan
googlenews
Oct 17, 2024
Funding-related
external-link
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial - StockTitan
googlenews
Sep 4, 2024
Science/business updates
external-link
Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles - Seeking Alpha
googlenews
Aug 26, 2024
Science/business updates
external-link
BTIG Maintains Buy on Outlook Therapeutics, L...
crunchbase
Nov 29, 2024
Science/business updates
external-link
Phase III AMD miss leaves BLA Outlook same with bevacizumab
crunchbase
Nov 27, 2024
Science/business updates
external-link
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
crunchbase
Nov 6, 2024
Science/business updates
external-link
Outlook Therapeutics Awaits Wet AMD Trial Results Of ONS-5010 - RTTNews
googlenews
Oct 10, 2024
Science/business updates
external-link
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
crunchbase
Mar 24, 2024
Science/business updates
external-link
Outlook Therapeutics sees significant insider buying by Syntone Ventures LLC By Investing.com
crunchbase
Apr 17, 2024
Funding-related
external-link
Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial
crunchbase
Nov 27, 2024
Science/business updates
external-link
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD - Yahoo Finance
googlenews
Mar 22, 2024
Science/business updates
external-link
NICE backs first ophthalmic bevacizumab for NHS use
crunchbase
Nov 5, 2024
Science/business updates
external-link
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial - GlobeNewswire
googlenews
Nov 27, 2024
Science/business updates
external-link
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutic - GuruFocus.com
googlenews
Dec 21, 2024
Funding-related
external-link
Outlook Therapeutics (OTLK) Announces NICE Recommendation of LYTENAVA for the Treatment of Wet AMD
crunchbase
Dec 4, 2024
Science/business updates
external-link
Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
googlenews
Dec 4, 2024
New hires
external-link
Together, we strive for better treatments in ophthalmology. Learn more about us: https://bit.ly/47dT9IJ
#OTLK #Ophthalmology #RetinaDisease #WetAMD
linkedin
Nov 27, 2024
Science/business updates
external-link
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
crunchbase
Dec 4, 2024
Science/business updates
external-link
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
crunchbase
Nov 27, 2024
Science/business updates
external-link
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference | Outlook Therapeutics, Inc.
linkedin
Nov 27, 2024
Science/business updates
external-link
Outlook Therapeutics (OTLK) Streamlines Operations
crunchbase
Dec 13, 2024
Science/business updates
external-link
Early detection of Wet AMD can significantly improve treatment outcomes. Get informed: https://bit.ly/3AaYOEI
#OTLK #ophthalmology #retinadisease #wetAMD
linkedin
Nov 27, 2024
Science/business updates
external-link
Thousands of people with a serious eye disease could be set to benefit after NICE today recommended a new treatment option.
Find out more about bevacizumab gamma for treating wet age-related macular
linkedin
Nov 27, 2024
Science/business updates
external-link
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
crunchbase
May 13, 2024
Science/business updates
external-link
© 2025 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com